The move shows a gap developing between Relay and Lilly in PI3Kα inhibition.
ApexOnco Front Page
Recent articles
An anti-ER “Riptac” enters phase 1.
The group impresses in ovarian and endometrial cancers.
After setbacks, cema-cel might have a path to approval in lymphoma.
The oncolytic virus vuso-vec is slapped with its second CRL.
After opting in last year, Gilead picks up Kymera's KT-200.
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The industry’s first ALK degrader starts its first human study.
